JP2013536195A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536195A5
JP2013536195A5 JP2013524318A JP2013524318A JP2013536195A5 JP 2013536195 A5 JP2013536195 A5 JP 2013536195A5 JP 2013524318 A JP2013524318 A JP 2013524318A JP 2013524318 A JP2013524318 A JP 2013524318A JP 2013536195 A5 JP2013536195 A5 JP 2013536195A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
chelate complex
pharmaceutical composition
complex comprises
chelate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536195A (ja
JP5775581B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2011/000956 external-priority patent/WO2012021985A1/en
Publication of JP2013536195A publication Critical patent/JP2013536195A/ja
Publication of JP2013536195A5 publication Critical patent/JP2013536195A5/ja
Application granted granted Critical
Publication of JP5775581B2 publication Critical patent/JP5775581B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524318A 2010-08-20 2011-08-18 オリゴヌクレオチドキレート錯体 Active JP5775581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37525710P 2010-08-20 2010-08-20
US61/375,257 2010-08-20
PCT/CA2011/000956 WO2012021985A1 (en) 2010-08-20 2011-08-18 Oligonucleotide chelate complexes

Publications (3)

Publication Number Publication Date
JP2013536195A JP2013536195A (ja) 2013-09-19
JP2013536195A5 true JP2013536195A5 (enExample) 2014-04-10
JP5775581B2 JP5775581B2 (ja) 2015-09-09

Family

ID=45594559

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524318A Active JP5775581B2 (ja) 2010-08-20 2011-08-18 オリゴヌクレオチドキレート錯体

Country Status (35)

Country Link
US (2) US8513211B2 (enExample)
EP (1) EP2605794B1 (enExample)
JP (1) JP5775581B2 (enExample)
KR (3) KR101606495B1 (enExample)
CN (2) CN103052405B (enExample)
AU (1) AU2011291401B2 (enExample)
BR (1) BR112013003875B1 (enExample)
CA (2) CA2855690C (enExample)
CL (1) CL2013000445A1 (enExample)
CO (1) CO6670525A2 (enExample)
CR (1) CR20130069A (enExample)
CU (1) CU20130022A7 (enExample)
CY (1) CY1118207T1 (enExample)
DK (1) DK2605794T3 (enExample)
DO (1) DOP2013000041A (enExample)
EA (1) EA026660B1 (enExample)
EC (1) ECSP13012449A (enExample)
ES (1) ES2598556T3 (enExample)
GT (1) GT201300040A (enExample)
HR (1) HRP20161333T1 (enExample)
HU (1) HUE029521T2 (enExample)
IL (1) IL224237A (enExample)
LT (1) LT2605794T (enExample)
MX (1) MX340294B (enExample)
MY (1) MY160961A (enExample)
NZ (1) NZ606364A (enExample)
PH (1) PH12013500192B1 (enExample)
PL (1) PL2605794T3 (enExample)
PT (1) PT2605794T (enExample)
RS (1) RS55245B1 (enExample)
SG (1) SG187165A1 (enExample)
SI (1) SI2605794T1 (enExample)
SM (1) SMT201600370B (enExample)
WO (1) WO2012021985A1 (enExample)
ZA (1) ZA201300497B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2049664T3 (da) 2006-08-11 2012-01-02 Prosensa Technologies Bv Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser
JP5646320B2 (ja) 2007-05-11 2014-12-24 アダイニクス， インコーポレイテッド 遺伝子発現と疼痛
EP2614827B1 (en) 2007-10-26 2017-06-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
EP3228712A1 (en) 2012-04-23 2017-10-11 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
PT2846839T (pt) * 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
MY168778A (en) * 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
BR112014033004B1 (pt) * 2012-07-03 2021-10-19 Biomarin Technologies B.V. Oligonucleotídeo para tratamento de pacientes com distrofia muscular
IN2015DN01087A (enExample) 2012-08-30 2015-06-26 Replicor Inc
CN113750112A (zh) 2014-07-10 2021-12-07 里普利科股份有限公司 治疗b型肝炎和d型肝炎病毒感染的方法
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
MX383293B (es) * 2015-04-23 2025-03-13 Geron Corp Metodos de preparacion de polinucleotidos usando composiciones salinas de cationes multivalentes.
BR112021008539A2 (pt) * 2018-11-08 2021-08-03 Aligos Therapeutics, Inc. polímeros de oligonucleotídeos e métodos de inibição de transporte de antígeno s
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20230250125A1 (en) 2020-04-01 2023-08-10 Janssen Biopharma, Inc. Nucleic acid polymers
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2300938A1 (en) * 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6653467B1 (en) * 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
JP4836366B2 (ja) * 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
WO2005023829A1 (ja) * 2003-09-02 2005-03-17 Japan Science And Technology Agency 金属錯体型核酸
WO2005026188A1 (ja) * 2003-09-08 2005-03-24 Japan Science And Technology Agency 金属錯体型核酸
CA2613101A1 (en) * 2005-07-01 2007-01-11 Bioveris Corporation Compositions and methods for detecting, amplifying, and/or isolating nucleic acids
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents

Similar Documents

Publication Publication Date Title
JP2013536195A5 (enExample)
PH12013500192B1 (en) Oligonucleotide chelate complexes
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2016512230A5 (enExample)
JP2013542247A5 (enExample)
JP2013507415A5 (enExample)
JP2013507439A5 (enExample)
US9370535B2 (en) Method for treatment of advanced solid tumors
JP2014510729A5 (enExample)
MX2010004089A (es) Compuestos metalicos mezclados para el tratamiento de hiperfosfatemia.
AU2012245080B2 (en) A method for the treatment of a solid tumour
SI2268292T1 (en) Method and compositions for the treatment of cancer
CA2672839A1 (en) Treatment of lung cancer with s-farnesylthiosalicylic acid and analogs thereof
JP2014530181A5 (enExample)
Douillard et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel–cisplatin versus vinorelbine–cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
JP2013544892A5 (enExample)
JP2012504584A5 (enExample)
WO2011031890A4 (en) Cancer stem cell-targeted and drug resistant cancer therapy
JP2012526099A5 (enExample)
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
WO2009096245A1 (ja) 医薬組成物又は組合せ剤
JP6758195B2 (ja) 併用ベースの治療方法
RU2014141615A (ru) Новое противоопухолевое средство, включающее комбинацию трех агентов
Chang et al. Administration of gemcitabine and cisplatin in cancer patients with renal failure under hemodialysis
JP2013227347A5 (enExample)